CN104857070A - Pharmaceutical composition used for resisting intestinal tract inflammatory injuries, and preparation method and applications thereof - Google Patents
Pharmaceutical composition used for resisting intestinal tract inflammatory injuries, and preparation method and applications thereof Download PDFInfo
- Publication number
- CN104857070A CN104857070A CN201410060376.1A CN201410060376A CN104857070A CN 104857070 A CN104857070 A CN 104857070A CN 201410060376 A CN201410060376 A CN 201410060376A CN 104857070 A CN104857070 A CN 104857070A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- preparation
- sophorae flavescentis
- radix sophorae
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicine, and discloses a pharmaceutical composition used for resisting intestinal tract inflammatory injuries, and a preparation method and applications thereof. The pharmaceutical composition is used for treating ulcerative colitis, and is prepared via combination of radix sophorae flavescentis and liquorice at a weight ratio of 1:0.25-4. The pharmaceutical composition is prepared via water extraction condensation. The pharmaceutical composition possesses excellent curative effect on ulcerative colitis, and the curative effect is better than that of radix sophorae flavescentis or liquorice.
Description
Technical field
The invention belongs to medical art, is pharmaceutical composition of a kind of anti-intestinal inflammatory damage and its production and use.
Background technology
Ulcerative colitis is the chronic nonspecific bowl inflammatory diseases that a kind of cause of disease is still not clear.The diseased region of ulcerative colitis mainly involves mucous membrane of colon and tela submucosa, clinical manifestation be continue or recurrent exerbation diarrhoea, mucus bloody purulent stool companion stomachache, tenesmus, stomatitis and abdomen block rare.
The therapeutic goal of ulcerative colitis is inflammation-inhibiting reaction as early as possible, relief of symptoms prevention of recurrence, improves patients ' life quality.At present, the treatment means of doctor trained in Western medicine is limited.Aminosalicylic acids and glucocorticoids are the conventional medicines for the treatment of ulcerative colitis.Minosalicylates, drugs onset is slow, and be mainly used in the treatment of slight ulcerative colitis, there are some researches show, clinical about have crowd's para-aminosalicylic acid class of 30% invalid.Glucocorticoid medicine can react by inflammation-inhibiting rapidly, relief of symptoms, but its long term administration can produce the Systemic reactions such as immunosuppressant.Monoclonal antibodies medicine is the new types of therapeutic agents in recent years developed, but the side effect widely because it is potential, at present only for the treatment for aminosalicylic acids and the out of contior ulcerative colitis of glucocorticoid medicine.
For the Drug therapy of ulcerative colitis, except chemicals, people are also actively finding the little Chinese medicine of determined curative effect, untoward reaction and extract thereof.Radix Sophorae Flavescentis glycyrrhiza decoction side goes out " a thousand pieces of gold " and rolls up 15, and name is shown in, and " Prescriptions for Universal Relief " rolls up 213, be mainly used in treatment dysentery more than.Side's Chinese crude drug has Radix Sophorae Flavescentis 3 liang, 3 liang, Radix Glycyrrhizae, dark yellow 3 liang, fermented soya beans, salted or other wise 1 liter half, Bulbus Allii Fistulosi 5 stem, another name for Sichuan Province green pepper 30." many wonderful celestial being sides " records, and old Radix Sophorae Flavescentis 350 grams, Radix Glycyrrhizae 350 grams, grind for end, decocting water with boiling medicine, can control dysentery by Rhizoma Zingiberis Recens 5 grams and old tea pugil.
Radix Sophorae Flavescentis has the effect of heat clearing away, dampness, parasite killing, cures mainly pyretic toxicity dysentery, discharging fresh blood stool and anal fistula etc.Modern pharmacology research is verified, the main active matrine of Radix Sophorae Flavescentis, oxymatrine can suppress the generation of ulcerative colitis in rats inflammatory cytokine Interleukin-1β, tumor necrosis factor-alpha, interleukin-6, interleukin-8, ICAM-1, improve superoxide dismutase content, reduce mda content, alleviate colitis damage, improve symptoms such as suffering from diarrhoea, have blood in stool.Radix Glycyrrhizae has effect of invigorating the spleen and replenishing QI, removing toxic substances, relieving spasm to stop pain.Radix Glycyrrhizae and active component Diammonium Glycyrrhizinate thereof have the non-specific antiinflammatory action of weak class hydrocortisone, can reduce the generation of tumor necrosis factor-alpha, ICAM-1 etc.
Current present situation is, although the symptom of dysentery described in the traditional Chinese medical science is as comparatively similar to the clinical manifestation of ulcerative colitis as described in modern medicine in stomachache, passing stool with blood and pus, tenesmus etc., but it has been common practise that the traditional Chinese medical science and modern medicine adhere to different theoretical systems separately, dysentery described in the traditional Chinese medical science is not equal to the ulcerative colitis described in modern medicine, and dysentery caused by such as, dysentery caused by infective enteritis and alimentary toxicosis does not just belong to the category of ulcerative colitis.Although Radix Sophorae Flavescentis Radix Glycyrrhizae prescription therapeutic dysentery has document and records, the effect of its treatment ulcerative colitis it be unclear that; Radix Sophorae Flavescentis Radix Glycyrrhizae prescription is only control symptom to the therapeutical effect of ulcerative colitis, still can eliminate the cause of disease also unclear; In addition, Radix Sophorae Flavescentis Radix Glycyrrhizae share with alone whether there are differences in curative effect also unclear.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art, pharmaceutical composition of a kind of anti-intestinal inflammatory damage and its production and use is provided.
The pharmaceutical composition of anti-intestinal inflammatory damage of the present invention, mainly with Radix Sophorae Flavescentis and Radix Glycyrrhizae for prepared by raw material, and the content weight ratio of Radix Sophorae Flavescentis and Radix Glycyrrhizae is Radix Sophorae Flavescentis: Radix Glycyrrhizae equals 1: 0.25 ~ 4.
The preparation method of the pharmaceutical composition of anti-intestinal inflammatory damage of the present invention: take each raw material by content weight ratio, by pulverizing, water extraction, each raw material blending is refined by concentrated mode, to obtain final product.
As a kind of optimal technical scheme of above-mentioned preparation method, its characterization step comprises: take each raw material by content weight ratio, beat coarse powder, decoct with water, and decocting liquid filters, and filtrate is concentrated into the extractum that relative density is 1.15g/ml ~ 1.35g/ml.
Gained extractum can dry, pulverize into fine powder further, sieves, and mixing, get dry extract powder.
As a kind of optimal technical scheme of above-mentioned preparation method, the soak by water of use raw materials quality 6 ~ 14 times of volumes 1 ~ 3 time, each 1 ~ 3 hour, continues subsequent step.
As a kind of optimal technical scheme of above-mentioned preparation method, the soak by water of use raw materials quality 10 ~ 12 times of volumes 2 ~ 3 times, each 2 ~ 3 hours, continues subsequent step.
As a kind of optimal technical scheme of above-mentioned preparation method, the soak by water of use raw materials quality 12 times of volumes 2 times, each 3 hours.
As a kind of optimal technical scheme of above-mentioned preparation method, the soak by water of use raw materials quality 10 times of volumes 2 times, each 2 hours.
Can preparation process conveniently, medical material, extractum, dried cream powder are added the conventional excipient substance such as excipient, flavoring agent, disintegrating agent, lubricant, wetting agent, binding agent, solvent, thickening agent, make the dosage form that any one is applicable to using clinically, as tablet, capsule, granule, solution etc.
The present invention is proved by modern pharmacology experiment, described pharmaceutical composition is better than Radix Sophorae Flavescentis for the therapeutic effect of ulcerative colitis or Radix Glycyrrhizae is individually dosed, pharmaceutical composition can not only damage by anti-ulcerative colitis intestinal inflammatory, suppress mucous membrane of colon swelling, reduce intestinal mucosa ulcer area, and significantly can suppress the generation of the key cytokines interleukin (IL)-13 in Ulcerative Colitis, fundamentally suppress developing of ulcerative colitis, play the therapeutical effect to disease.In addition, we with the serum levels of important inflammatory cytokine tumor necrosis factor (the TNF)-α of ulcerative colitis for index, pharmaceutical composition obtained under have studied Radix Sophorae Flavescentis, Radix Glycyrrhizae various dose proportioning is on the impact of Ulcerative Colitis Model mice serum TNF-alpha content, when result shows that the content weight ratio of Radix Sophorae Flavescentis and Radix Glycyrrhizae is in 1: 0.25 ~ 4 scopes, obtained pharmaceutical composition has the effect of Synergistic.Above-mentioned experimental result sufficient proof also embodies, the application of pharmaceutical composition of the present invention in preparation treatment ulcerative colitis medicine.
Detailed description of the invention
Embodiment 1
At room temperature, take Radix Sophorae Flavescentis 4.17 kilograms, 0.83 kilogram, Radix Glycyrrhizae (totally 5 kilograms), beat coarse powder, add 30 kilograms of (6 times) soak by water 2 times, each 3 hours, decocting liquid filtered, and filtrate conventional vacuum is concentrated into the extractum that relative density is 1.25g/ml.
Embodiment 2
At room temperature, take Radix Sophorae Flavescentis 3.57 kilograms, 1.43 kilograms, Radix Glycyrrhizae (totally 5 kilograms), beat coarse powder, add 70 kilograms of (14 times) soak by water 1 time, 2.5 hours, decocting liquid filtered, and filtrate conventional vacuum is concentrated into the extractum that relative density is 1.15g/ml.
Embodiment 3
At room temperature, take Radix Sophorae Flavescentis 2.5 kilograms, 2.5 kilograms, Radix Glycyrrhizae (totally 5 kilograms), beat coarse powder, add 50 kilograms of (10 times) soak by water 2 times, each 2 hours, decocting liquid filtered, and filtrate conventional vacuum is concentrated into the extractum that relative density is 1.20g/ml.
Embodiment 4
At room temperature, take Radix Sophorae Flavescentis 1.43 kilograms, 3.57 kilograms, Radix Glycyrrhizae (totally 5 kilograms), beat coarse powder, add 60 kilograms of (12 times) soak by water 3 times, each 1 hour, decocting liquid filtered, and filtrate conventional vacuum is concentrated into the extractum that relative density is 1.35g/ml.
Embodiment 5
At room temperature, take Radix Sophorae Flavescentis 0.83 kilogram, 4.17 kilograms, Radix Glycyrrhizae (totally 5 kilograms), beat coarse powder, add 40 kilograms of (8 times) soak by water 3 times, each 1.5 hours, decocting liquid filtered, and filtrate conventional vacuum is concentrated into the extractum that relative density is 1.30g/ml.
Embodiment 6
At room temperature, take Radix Sophorae Flavescentis 3.57 kilograms, 1.43 kilograms, Radix Glycyrrhizae (totally 5 kilograms), beat coarse powder, add 50 kilograms of (10 times) soak by water 2 times, each 2 hours, decocting liquid filters, and filtrate conventional vacuum is concentrated into the extractum that relative density is 1.25g/ml, then continues to dry at 50-60 DEG C, be crushed to fine powder, sieve, mixing, get dry extract powder.
Above-mentioned experiment content instrument illustrates, not for limiting the scope of the invention as further explanation of the present invention.
Experimental example 1
Radix Sophorae Flavescentis and licorice medicinal materials purchased from Xi'an Chinese Medicinal Materials Markets, and are identified through laboratory professor Wang Qingwei.
According to content assaying method under Chinese Pharmacopoeia 2010 editions Radix Sophorae Flavescentiss and Radix Glycyrrhizae item, the content recording oxymatrine in Sophora flavescens is 1.62%, and in licorice medicinal materials, the content of glycyrrhizic acid is 4.66%.
Sophora flavescens and licorice medicinal materials are beaten coarse powder respectively, mixes after respectively taking 50g, adopt extraction process by water, using amount of water, decocting time, decoction number of times as investigation factor, each factor gets 3 levels (see table 1), adopts L
9(3
4) table carries out orthogonal test, with the comprehensive grading of the extraction ratio of oxymatrine and glycyrrhizic acid for inspection target, study the impact of each factor on extraction effect, result of the test is in table 2.
Table 1 experimental factor table
Table 2 orthogonal test scheme and result
Comprehensive grading=(oxymatrine extraction ratio+glycyrrhizic acid extraction ratio)/2
Intuitive analysis result shows, the primary and secondary order of each factor to the effect of extraction process by water extraction ratio comprehensive grading is C > B > A, and Optimized extraction techniques is A
3b
2c
3, namely amount of water is 12 times of medical material amounts, and each decoction 2 hours, decocting number of times is 3 times.
Consider the needs that industrialized great production reduces costs, in conjunction with orthogonal experiments, we are to extraction process A
3b
2c
3and A
2b
2c
2be repeated and carry out this test, the comprehensive grading of both contrasts extraction ratio, obtained experimental result is in table 3.
The result of the test of table 3 Optimized extraction techniques
Result shows, extraction process A
2b
2c
2comprehensive grading only than A
3b
2c
3low by 3.44%, consider and adopt A
2b
2c
2extraction process compares A
3b
2c
3significantly can reduce energy consumption, and can save time, therefore Optimized extraction techniques is, amount of water is 10 times of medical material amounts, and decocting number of times is 2 times, each 2 hours.
Experimental example 2
The pharmaceutical composition of anti-intestinal inflammatory damage is to the therapeutical effect of the colitis in mice that dextran sulfate sodium (DSS) is induced.
According to the preparation method of embodiment 3, prepare the water extracted immersing paste of 5 kilograms of Radix Sophorae Flavescentis raw materials, 5 kilograms of licorice raw materials and 2.5 kilograms of Radix Sophorae Flavescentiss and 2.5 kilograms of Radix Glycyrrhizae mixed materials (adding up to 5 kilograms) respectively, then continue respectively to dry at 50-60 DEG C, be crushed to fine powder, sieve, mixing, the powder that gets dry extract is for subsequent use.
DSS available from Sigma.Myeloperoxidase (MPO) (MPO) activity detection kit builds up biological study institute purchased from Nanjing.By 70 C57BL/6 male mices, body weight 20 ± 2g, is divided into 7 groups, often organizes 10.Normal group normal water, feed, all the other are respectively organized and freely drink 5%DSS solution (DSS of 5mg molecular weight 36000-50000 is dissolved in 100ml distilled water) 7 days, simultaneously gavage gives to intervene medicine or solvent control every day 1 time, and each group is by following dosed administration.
Radix Sophorae Flavescentis extract group: by Radix Sophorae Flavescentis dried cream powder, by 5g/kg (raw material/Mouse Weight) dosage, gavage after distilled water dispersion; Radix Glycyrrhizae extract group: by Radix Glycyrrhizae dried cream powder, by 5g/kg (raw material/Mouse Weight) dosage, gavage after distilled water dispersion; Pharmaceutical composition low dose group: by pharmaceutical composition dried cream powder, by 2.5g/kg (mixed material/Mouse Weight) dosage, gavage after distilled water dispersion; Dosage group in pharmaceutical composition: by pharmaceutical composition dried cream powder, by 5g/kg (mixed material/Mouse Weight) dosage, gavage after distilled water dispersion; Pharmaceutical composition high dose group: by pharmaceutical composition dried cream powder, by 10g/kg (mixed material/Mouse Weight) dosage, gavage after distilled water dispersion; Model control group gavage equivalent distilled water.Each group every day gavage 1 time, continuous 7 days, after last gavage 8 hours, put to death after mouse weights, get the above intestinal tissue of anus 4 centimetres, cut off along the longitudinal axis, rinsed well by content with 4 DEG C of normal saline, mucosa is upwards laid on ice cube, and overlay is placed on it, draw ulcer surface, calculate ulcer area percentage ratio, weigh blot the moisture in colon with filter paper after, then get segmental colonic tissue, by the operation of detection kit description, measure Ge Zu colon MPO enzymatic activity respectively.
Table 4 pharmaceutical composition is to the protective effect of the colitis in mice that DSS induces.(mean±SD，n＝10)
△ P < 0.05 and Normal group ratio;
*p < 0.05 and model control group ratio; & P < 0.05 and Radix Sophorae Flavescentis or Radix Glycyrrhizae one-component ratio; #P < 0.05 and dosage group ratio in pharmaceutical composition.
After mice modeling, mucous membrane of colon is congested, edema, and local mucous membrane comes off, ulcer.Colon MPO enzymatic activity significantly improves, and embodies the inflammatory reaction degree of model mice colon.Colon/weight ratio increases, and embodies the degree of the congested swelling of intestinal mucosa.The raising of ulcer area percentage ratio embodies the significant Histopathological characteristics of ulcerative colitis.Radix Sophorae Flavescentis extract group and Radix Glycyrrhizae extract group all can reduce the ulcer area percentage ratio of ulcerative colitis in rats, suppress MPO active, reduce colon/weight ratio, show Radix Sophorae Flavescentis extract and the individually dosed symptom can improving ulcerative colitis mice of Radix Glycyrrhizae extract under 5g/kg (raw material/Mouse Weight) dosage.It should be noted that, each index of pharmaceutical composition low dose group 2.5g/kg (mixed material/Mouse Weight) and the therapeutical effect no difference of science of statistics of Radix Sophorae Flavescentis extract group or Radix Glycyrrhizae extract group, when pharmaceutical composition group dosage and Radix Sophorae Flavescentis extract group or Radix Glycyrrhizae extract group are all 5g/kg, every treatment index of pharmaceutical composition group is all better than Radix Sophorae Flavescentis extract group and Radix Glycyrrhizae extract group, show that Radix Sophorae Flavescentis Radix Glycyrrhizae share rear Synergistic, be better than alone.Pharmaceutical composition high dose group curative effect is better than middle dosage group further, shows that the therapeutical effect of pharmaceutical composition to ulcerative colitis is dose dependent.
Experimental example 3
The pharmaceutical composition of anti-intestinal inflammatory damage is on the impact of the colonic lamina propria Expressions In Lymphocytes IL-13 of DSS induced ulcerative colitis mice.
CD
3monoclonal antibody, CD
28monoclonal antibody, IL-13 enzyme-linked immunologic detecting kit (ELISA) are all purchased from Beijing, and to reach section be Bioisystech Co., Ltd.
By dosage treatment group gained colon in the Normal group in experimental example 2, model control group, pharmaceutical composition, preparation and purification intestinal mucosa lamina propria mononuclear cell (LPMC) as follows.Key step is: colon's specimen adds the HBSS liquid without calcium, magnesium ion after cleaning and remove the mucosa on surface, is placed in water bath shake and hatches.Culture fluid is changed once for every 30 minutes, until not containing epithelial cell in supernatant.Then tissue specimen is cut into 1-2mm
3the fragment of size, be placed in containing 10% hyclone, 0.5mg/ml Gelatinase B, 1mg/ml hyaluronidase, 0.1mg/ml DNase I, carry out hatching digestion in the RPMI1640 culture fluid of 50mg/ml amphotericin B, 50mg/ml gentamycin, 100U/ml penicillin and 100mg/ml streptomycin.Filter and centrifugal segregation epithelial cell and other large granule cells through nylon screen.Be separated with Ficoll-Hypaque separating medium and obtain LPMC.Cell concentration is adjusted to 10
6individual/ml, is having stimulant (the anti-CD of 10 μ g/ml
3the anti-CD of monoclonal antibody+1 μ g/ml
28monoclonal antibody) or non-stimulated dose of existent condition under, be placed in 37 DEG C of 5%CO
2in incubator, 48 h before harvest supernatant.To specifications, ELISA method measures the concentration of IL-13 in cell culture fluid.
Table 5 DSS mouse Colon organizes LPMC to secrete the level (mean ± SD, pg/ml, n=10) of IL-13
△ P < 0.05 and Normal group ratio;
*p < 0.05 and model control group ratio.
The LPMC of normal mouse colon does not generate IL-13 under non-stimulated dose of existent condition, a small amount of IL-13 is only generated when adding stimulant, and the LPMC at DSS model mice colonic pathological change position is under non-stimulated dose of existent condition, can a large amount of IL-13 of spontaneous generation, after adding stimulant, produce the more notable raising of level of IL-13.By contrast, after pharmaceutical composition administration is intervened, diseased region LPMC can be suppressed to generate IL-13, show as medicine composite for curing group at non-stimulated dose and have a stimulant, in supernatant, the level of IL-13 is all lower than corresponding model group.
IL-13 is the key cytokines in Ulcerative Colitis, our result of the test shows, pharmaceutical composition of the present invention can generate IL-13 by suppressing intestinal mucosa lamina propria mononuclear cell, fundamentally suppress developing of ulcerative colitis, play the therapeutical effect to disease.
Experimental example 4
Pharmaceutical composition obtained under Radix Sophorae Flavescentis, Radix Glycyrrhizae various dose proportioning is on the impact of Ulcerative Colitis Model mice serum TNF-alpha content.
The ELISA kit of TNF-α is purchased from Nanjing and builds up biological study institute.
According to the preparation method of embodiment 3, with the proportioning raw materials in table 5, pharmaceutical compositions.Dosage regimen is with experimental example 2.After last administration 8 hours, mouse orbit got blood, and after whole blood leaves standstill 30min, 3000 rpms centrifugal 20 minutes, separation of serum, and then by specification measures the content of TNF-α in serum.
Pharmaceutical composition obtained under table 6 various dose proportioning is on the impact (mean ± SD, ng/L, n=10) of ulcerative colitis mice serum TNF-alpha levels
△ P < 0.05 and Normal group ratio;
*p < 0.05 and model comparison ratio; & P < 0.05vs Radix Sophorae Flavescentis or Radix Glycyrrhizae one-component ratio.
Experimental result shows, model control group mice serum TNF-alpha levels is compared Normal group and significantly raised, and each administration group can reduce serum TNF-cc level in varying degrees.When the content weight ratio of Radix Sophorae Flavescentis and Radix Glycyrrhizae is Radix Sophorae Flavescentis: when Radix Glycyrrhizae equals 1: 0.25 ~ 4, the pharmaceutical composition of preparation compares Radix Sophorae Flavescentis or the administration of Radix Glycyrrhizae one-component can reduce serum TNF-cc level further, show that now curative effect strengthens, and has the prescription advantage of Synergistic.
Claims (8)
1. the pharmaceutical composition of anti-intestinal inflammatory damage, it is characterized in that it mainly with Radix Sophorae Flavescentis and Radix Glycyrrhizae for prepared by raw material, and the content weight ratio of Radix Sophorae Flavescentis and Radix Glycyrrhizae is Radix Sophorae Flavescentis: Radix Glycyrrhizae equals 1: 0.25 ~ 4.
2. the preparation method of the pharmaceutical composition of anti-intestinal inflammatory damage according to claim 1, comprise the following steps: take each raw material by content weight ratio, beat coarse powder, decoct with water, decocting liquid filters, and filtrate is concentrated into the extractum that relative density is 1.15g/ml ~ 1.35g/ml.
3. the preparation method of pharmaceutical composition according to claim 2, is characterized in that gained extractum dry, pulverize into fine powder further, sieves, and mixing, get dry extract powder.
4. the preparation method of the pharmaceutical composition according to claim 2,3, is characterized in that using the soak by water 1 ~ 3 time of raw materials quality 6 ~ 14 times of volumes, each 1 ~ 3 hour, continues subsequent step.
5. the preparation method of pharmaceutical composition according to claim 4, is characterized in that using the soak by water 2 ~ 3 times of raw materials quality 10 ~ 12 times of volumes, each 2 ~ 3 hours, continues subsequent step.
6. the preparation method of pharmaceutical composition according to claim 4, is characterized in that using the soak by water 2 times of raw materials quality 12 times of volumes, each 3 hours.
7. the preparation method of pharmaceutical composition according to claim 4, is characterized in that using the soak by water 2 times of raw materials quality 10 times of volumes, each 2 hours.
8. the application of pharmaceutical composition according to claim 1 in preparation treatment ulcerative colitis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410060376.1A CN104857070A (en) | 2014-02-24 | 2014-02-24 | Pharmaceutical composition used for resisting intestinal tract inflammatory injuries, and preparation method and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410060376.1A CN104857070A (en) | 2014-02-24 | 2014-02-24 | Pharmaceutical composition used for resisting intestinal tract inflammatory injuries, and preparation method and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104857070A true CN104857070A (en) | 2015-08-26 |
Family
ID=53903537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410060376.1A Pending CN104857070A (en) | 2014-02-24 | 2014-02-24 | Pharmaceutical composition used for resisting intestinal tract inflammatory injuries, and preparation method and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104857070A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108743656A (en) * | 2018-09-17 | 2018-11-06 | 石磊 | Kuh-seng Radix Glycyrrhizae prescription for treating non-alcohol fatty liver |
| CN111053803A (en) * | 2020-01-14 | 2020-04-24 | 南京中医药大学 | Composition with anti-staphylococcus aureus effect and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768780A (en) * | 2004-11-04 | 2006-05-10 | 杨明 | Pharmaceutical composition for treating ulcerative colitis, its preparation method and use |
| CN101700358A (en) * | 2009-11-12 | 2010-05-05 | 林喜彬 | Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof |
| CN103202920A (en) * | 2013-02-15 | 2013-07-17 | 天津中医药大学 | Traditional Chinese medicine composition with antibacterial function |
-
2014
- 2014-02-24 CN CN201410060376.1A patent/CN104857070A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768780A (en) * | 2004-11-04 | 2006-05-10 | 杨明 | Pharmaceutical composition for treating ulcerative colitis, its preparation method and use |
| CN101700358A (en) * | 2009-11-12 | 2010-05-05 | 林喜彬 | Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof |
| CN103202920A (en) * | 2013-02-15 | 2013-07-17 | 天津中医药大学 | Traditional Chinese medicine composition with antibacterial function |
Non-Patent Citations (1)
| Title |
|---|
| 高学敏，钟赣生: "《临床中药学》", 31 January 2006, 河北科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108743656A (en) * | 2018-09-17 | 2018-11-06 | 石磊 | Kuh-seng Radix Glycyrrhizae prescription for treating non-alcohol fatty liver |
| CN111053803A (en) * | 2020-01-14 | 2020-04-24 | 南京中医药大学 | Composition with anti-staphylococcus aureus effect and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112386635A (en) | Application of Jingfang preparation in preparing medicine for treating new coronary sequelae and preparation method thereof | |
| CN102085252B (en) | Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN104857070A (en) | Pharmaceutical composition used for resisting intestinal tract inflammatory injuries, and preparation method and applications thereof | |
| CN105343260B (en) | The drug for treating chronic ulcerative colitis | |
| CN105194460A (en) | Traditional Chinese medicine preparation for treating acute episode stage of wind-damp-heat type gout | |
| CN101850063A (en) | Medicinal preparation for preventing and treating gout and preparation method | |
| CN102048841A (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN101181349B (en) | Application of Salvia przewalskii Maxim extract in the preparation of medicament for curing nephritis of renal glomerulus | |
| CN101428111B (en) | Traditional Chinese medicine compound formulation for treating habitual constipation and preparation method thereof | |
| CN108126011B (en) | Pharmaceutical composition for auxiliary conditioning of patients undergoing tumor radiotherapy and chemotherapy and preparation method thereof | |
| CN103041288B (en) | A kind of Chinese medicine composition and preparation technology treating diabetic fatty liver | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN105497167A (en) | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis | |
| CN1269501C (en) | Medicine for treating chronic colitis and its preparing process | |
| CN1970001B (en) | Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN110064016A (en) | A kind of Chinese medicine composition and preparation method thereof adjusting chronic kidney disease immune state | |
| CN104095912A (en) | Traditional Chinese medicine formula for treating rheumatism bone disease and preparation method of Chinese patent medicine of traditional Chinese medicine formula | |
| CN115715782B (en) | Traditional Chinese medicine composition for preventing and treating ulcerative colitis and application thereof | |
| CN114984113B (en) | Traditional Chinese medicine composition for treating liver fibrosis and preparation method and application thereof | |
| CN107595937B (en) | Combined spicebush root composition with inflammatory bowel disease antagonism and application thereof | |
| CN104208126A (en) | New formula for preventing and treating nephrosis syndrome and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150826 |